IL-13Rα2 humanized scFv-based CAR-T cells exhibit therapeutic activity against glioblastoma

Molecular Therapy: Oncolytics

Zhijing An¹  Yue Bai¹  Can Zhang¹  Yi Hu¹  Xiaosong Zhong¹  Chang Xu¹ 

[1] The Clinical Center of Gene and Cell Engineering, Beijing Shijitan Hospital, Capital Medical University, No. 10, Iron Medicine Road, Yang Fang Dian, Haidian District, Beijing, China;

关键词: interleukin-13 receptor α2;    chimeric antigen receptor-modified T cells;    glioblastoma;    adoptive T cell therapy;    expansion;    cytokine;   

DOI  :  

来源: DOAJ

【 摘 要 】

Chimeric antigen receptor (CAR)-modified T cells have exhibited impressive anti-tumor effects in both B cell malignancies and some types of solid tumors. However, single-chain variable fragment (scFv) of a murine monoclonal antibody will induce immune responses, limit CAR-T cell persistence, and thus increase the risk of relapse. This study successfully constructed a CAR-targeting interleukin-13 receptor α2 (IL-13Rα2) according to a murine antibody, and then humanized the scFv sequence to generate another CAR. T cells expressing any of these two CARs demonstrated superior tumor inhibitory effects in vitro and in two xenograft mouse models. However, T cells transduced with humanized CAR have an increased expansion and reduced cytokines, including interleukin-6 and interferon-γ. The top expressed genes clustered in leukocyte-mediated cytotoxicity, and T cell migration and immunological synapse formation contributed to the anti-glioblastoma (GBM) activity of the humanized CAR. In conclusion, we successfully generated a humanized third-generation CAR-targeting IL-13Rα2 and confirmed its anti-GBM efficacy, which provide a candidate method for clinical GBM treatment.

【 授权许可】

Unknown